NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Metagenomi, Inc. (“Metagenomi” or “the Company”) (NASDAQ: MGX). Investors who purchased Metagenomi securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MGX.

Investigation Details

On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”). The Company sold about 6.25 million shares at $15 per share as part of the IPO, but less than two months later, Metagenomi announced that it and Moderna had “mutually agreed to terminate their collaboration.”

What's Next?

If you are aware of any facts relating to this investigation or purchased Metagenomi securities, you can assist this investigation by visiting the firm’s site: bgandg.com/MGX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.